薬の用量の違いによるNN0519-0130の2型糖尿病患者の血糖降下効果を比較した研究研究
2型糖尿病の参加者における週1回のNNC0519-0130の安全性と有効性の調査 - 用量調査研究
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Chula Vista、California、アメリカ、91911
- Velocity Clin Res-Chula Vista
-
Fresno、California、アメリカ、93720
- Valley Research
-
Inglewood、California、アメリカ、90301
- 310 Clinical Research
-
La Mesa、California、アメリカ、91942
- Velocity Clin Res San Diego
-
Lancaster、California、アメリカ、93534
- First Valley Med Grp Lancaster
-
Lomita、California、アメリカ、90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos、California、アメリカ、90720
- Pacific Clinical Studies
-
Los Angeles、California、アメリカ、90057
- Velocity Clinical Research Westlake
-
Montclair、California、アメリカ、91763
- Catalina Research Institute, LLC
-
San Diego、California、アメリカ、92123
- Artemis Insitute for Clin Res
-
Toluca Lake、California、アメリカ、91602
- Med Partners, Inc.
-
Torrance、California、アメリカ、90505
- UCLA Health Southbay Endocrine
-
Tustin、California、アメリカ、92780
- University Clin Investigators
-
Walnut Creek、California、アメリカ、94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater、Florida、アメリカ、33756
- Innovative Research of W Florida Inc.
-
Clearwater、Florida、アメリカ、33756
- Innovative Research of W FL
-
Miami、Florida、アメリカ、33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus、Georgia、アメリカ、31904
- Centricity Research
-
-
Idaho
-
Blackfoot、Idaho、アメリカ、83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria、Illinois、アメリカ、61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa
-
-
Maryland
-
Columbia、Maryland、アメリカ、21045
- Centennial Medical Group
-
Oxon Hill、Maryland、アメリカ、20745
- MD Medical Research
-
Rockville、Maryland、アメリカ、20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield、Missouri、アメリカ、65807
- Clinvest Research
-
-
Montana
-
Butte、Montana、アメリカ、59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln、Nebraska、アメリカ、68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89148
- Palm Research Center Inc-Vegas
-
Las Vegas、Nevada、アメリカ、89109
- Excel Clinical Network
-
-
New York
-
Binghamton、New York、アメリカ、13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro、North Carolina、アメリカ、27408
- PharmQuest Life Sciences LLC
-
Wilmington、North Carolina、アメリカ、28401
- Accellacare Wilmington
-
-
Ohio
-
Canton、Ohio、アメリカ、44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati、Ohio、アメリカ、45242
- Velocity Clin Res_Cincinnati
-
Cincinnati、Ohio、アメリカ、45246
- Velocity Clinical Research Springdale
-
Dayton、Ohio、アメリカ、45439
- Providence Health Partners Ctr
-
Maumee、Ohio、アメリカ、43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass、Oregon、アメリカ、97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19114
- Tristar Clin Investigations, PC
-
Pittsburgh、Pennsylvania、アメリカ、15243
- Preferred Primary Care Physicians Inc.
-
Uniontown、Pennsylvania、アメリカ、15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene、Texas、アメリカ、79606
- Velocity Clinical Research Abilene
-
Austin、Texas、アメリカ、78759
- Velocity Clin Res Austin
-
Dallas、Texas、アメリカ、75390
- UT Southwestern Med Center
-
Dallas、Texas、アメリカ、75230
- Velocity Clinical Res-Dallas
-
Dallas、Texas、アメリカ、75230
- Zenos Clinical research
-
Forney、Texas、アメリカ、75126
- Care United Research, LLC
-
Houston、Texas、アメリカ、77004
- Endocrine Associates Houston
-
Houston、Texas、アメリカ、77043
- Biopharma Informatic_Houston
-
Irving、Texas、アメリカ、75039
- Tekton Research
-
Lewisville、Texas、アメリカ、75057
- Epic Clinical Research
-
Shavano Park、Texas、アメリカ、78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke、Virginia、アメリカ、22015
- Burke Internal Medicine & Research
-
Newport News、Virginia、アメリカ、23606
- TPMG Clinical Research
-
-
-
-
-
Bengaluru、インド、560054
- MS Ramaiah
-
New Delhi、インド、110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore、Karnataka、インド、560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi、Kerala、インド、682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore、Madhya Pradesh、インド、452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai、Maharashtra、インド、400012
- Seth GS Medical College & KEM Hospital
-
Pune、Maharashtra、インド、411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur、Rajasthan、インド、302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore、Tamil Nadu、インド、632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad、Telangana、インド、500082
- Diabetes Research Center, Hyderabad
-
-
-
-
New South Wales
-
Campbelltown、New South Wales、オーストラリア、2560
- Campbelltown Hospital
-
Macquarie Park、New South Wales、オーストラリア、2109
- Macquarie University - Clinical Trials Unit
-
St Leonards、New South Wales、オーストラリア、2065
- Royal North Shore Hospital
-
Sydney、New South Wales、オーストラリア、2148
- Western Endocrine Blacktown
-
Sydney、New South Wales、オーストラリア、2148
- Roger Chih Yu Chen
-
Wollongong、New South Wales、オーストラリア、2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya、Queensland、オーストラリア、4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook、Queensland、オーストラリア、4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park、South Australia、オーストラリア、5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill、Victoria、オーストラリア、3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell、Victoria、オーストラリア、3124
- Emeritus Research Melbourne
-
Heidelberg Heights、Victoria、オーストラリア、3081
- Austin Health, Metabolic Disorders Centre
-
Parkville、Victoria、オーストラリア、3050
- The Royal Melbourne Hospital
-
Parkville、Victoria、オーストラリア、3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle、Western Australia、オーストラリア、6160
- Fremantle Hospital
-
-
-
-
-
Québec、カナダ、G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna、British Columbia、カナダ、V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond、British Columbia、カナダ、V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria、British Columbia、カナダ、V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton、New Brunswick、カナダ、E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie、Ontario、カナダ、L4N 7L3
- Centricity Research Barrie
-
Hamilton、Ontario、カナダ、L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia、Ontario、カナダ、N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto、Ontario、カナダ、M4G 3E8
- Centricity Research Toronto
-
Toronto、Ontario、カナダ、M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis、Quebec、カナダ、G6W 0M5
- Centricity Research Quebec City
-
Mirabel、Quebec、カナダ、J7J 2K8
- Centricity Research Mirabel
-
Montreal、Quebec、カナダ、H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent、Quebec、カナダ、H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
Free State
-
Bloemfontein、Free State、南アフリカ、9301
- Josha Research
-
-
Gauteng
-
Johannesburg、Gauteng、南アフリカ、2013
- Wits Bara Clinical Trial Site
-
Midrand、Gauteng、南アフリカ、1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban、KwaZulu-Natal、南アフリカ、4450
- Dr Pillay's Rooms
-
eMkhomazi、KwaZulu-Natal、南アフリカ、4170
- Dr T Padayachee
-
-
-
-
-
Chiba、日本、261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama、日本、340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo、日本、104-0031
- Fukuwa Clinic
-
Tokyo、日本、103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo、日本、104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
-
Seoul、韓国、05505
- Asan Medical Center
-
Seoul、韓国、01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul、韓国、03181
- Kangbuk Samsung Hospital
-
Seoul、韓国、02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si、Gyeonggi-do、韓国、13620
- Seoul National University Bundang Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
プラセボコンパレーター:Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
実験的:Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
プラセボコンパレーター:Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
実験的:Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
プラセボコンパレーター:Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
実験的:Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
プラセボコンパレーター:Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
実験的:Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
プラセボコンパレーター:Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
アクティブコンパレータ:Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
時間枠:From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
時間枠:From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
時間枠:From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
時間枠:From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Transparency (dept. 2834)、Novo Nordisk A/S
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- NN9541-4945
- U1111-1291-9196 (その他の識別子:World Health Organization (WHO))
- jRCT2031230704 (レジストリ識別子:JRCT)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。